Lilly(Eli) & Co

NYSE:LLY   3:59:59 PM EDT
307.78
+7.59 (+2.53%)
4:07:39 PM EDT: $307.49 -0.29 (-0.09%)
Other Pre-Announcement

Lilly Reports Second-Quarter Financial Results

Published: 08/04/2022 10:38 GMT
Lilly(Eli) & Co (LLY) - Lilly Reports Second-quarter Financial Results, Highlights Momentum of New Medicines and Pipeline Advancements.
Q2 Earnings per Share $1.05.
Q2 Revenue Fell 4 Percent to $6.49 Billion.
Eli Lilly - 2022 EPS Guidance Updated to Be in Range of $6.96 to $7.11 on a Reported Basis and $7.90 to $8.05 on a Non-GAAP Basis.
Eli Lilly - Revenue Guidance for 2022 Remains Unchanged.
Eli Lilly - for Q2 2022, Worldwide Trulicity Revenue Was $1.91 Billion, an Increase of 25% Compared With Q2 2021.
Eli Lilly - for Q2 2022, Worldwide Taltz Revenue Increased 7% Compared With Q2 2021, to $606.2 Million.
Eli Lilly - Expect That Our Financial Results Will Continue to Be Negatively Impacted by Foreign Exchange Rates.
Eli Lilly - for Q2 2022, Worldwide Humalog Revenue Decreased 26% Compared With Q2 2021, to $447.1 Million.
Q2 Earnings per Share View $1.69, Revenue View $6.84 Billion -- Refinitiv Ibes Data (analyst estimates).
FY2022 Earnings per Share View $8.28, Revenue View $29.13 Billion -- Refinitiv Ibes Data (analyst estimates).
Eli Lilly - for Q2 2022, Worldwide Olumiant Revenue Decreased 11% Compared With Q2 2021, to $186.2 Million.
Eli Lilly - Lowered Non-GAAP EPS Guidance by $0.25 to Now Be in Range of $7.90 to $8.05 for 2022.
Eli Lilly - U.S. FDA Accepted, With Priority Review Designation, Donanemab for Alzheimer's Disease for Review Under Accelerated Approval Pathway.